Peer-reviewed veterinary case report
Blood and bone marrow involvement in new canine lymphoma prognosis
By Marconato, Laura et al.·Published in Veterinary journal (London, England : 1997)·2019·Centro Oncologico Veterinario, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prognostic significance of peripheral blood and bone marrow infiltration in newly-diagnosed canine nodal marginal zone lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with nodal marginal zone lymphoma (nMZL) were studied to see how the amount of cancer in their blood and bone marrow affected their survival and progression of the disease. The results showed that dogs with less than 30% cancer in their blood lived longer before the disease worsened, averaging 186 days, compared to those with 30% or more, who averaged only 43 days. Additionally, dogs with less than 1% cancer in their bone marrow had a median survival of over 1,400 days, while those with higher levels had significantly shorter lives. Treatments like chemo-immunotherapy and normal blood levels also helped improve survival times.
People also search for: dog lymphoma prognosis · canine cancer treatment options · nMZL survival rates · dog blood cancer symptoms · chemo-immunotherapy for dogs
Abstract
Canine nodal marginal zone lymphoma (nMZL) is infrequent and is typically diagnosed at an advanced disease stage. However, it is currently unknown whether different levels of peripheral blood (PB) and bone marrow (BM) infiltration may provide prognostic stratification in dogs with nMZL. The aims of the present prospective study were to assess the influence of PB and BM infiltration detected by flow cytometry (FC) on time to progression (TTP) and lymphoma-specific survival (LSS) in dogs with newly-diagnosed multicentric nMZL, and to establish a cut-off value of prognostic significance. Forty-five completely staged and treatment-naïf dogs with histologically-confirmed nMZL were enrolled. After staging, dogs received chemo-immunotherapy or chemotherapy. PB infiltration was significantly associated with TTP (p=0.001): dogs with PB infiltration <30% had a median TTP of 186 days, whereas dogs with PB infiltration ≥30% had a median TTP of 43 days. Additionally, vaccinated dogs had a significantly (p=0.012) longer TTP (399 days) compared with dogs receiving chemotherapy only (211 days). BM infiltration was significantly associated with LSS (p<0.001): dogs with BM infiltration <1% had a median LSS of 1403 days, those with BM infiltration 1-20% of 337 days, and those with BM infiltration ≥20% of 188 days. Normal LDH levels and the administration of chemo-immunotherapy also significantly improved LSS (560 vs 211 days, and 399 vs 211 days, respectively; p<0.001). PB and BM flow cytometric evaluation is an integral part of staging work-up in dogs with nMZL and has prognostic relevance.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30902194/